Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Academic Radiology|January 14, 2023
Factors and Labor Cost Savings Associated with Successful Pediatric Imaging without Anesthesia: a Single-Institution StudyJoshua Vic Chen, Matthew A Zapala, Alice Zhou, et al.
Journal of Medical Extended Reality|August 6, 2026
Improving Patient Education Using Augmented Reality for Spine Fractures: Feasibility Study and Review of LiteratureDavid J Mazur-Hart, Jamila A Godil, Brandi W Pang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) TrialSteven G DuBois, Araz Marachelian, Elizabeth Fox, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2015
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II studyGregory A Yanik, Judith G Villablanca, John M Maris, et al.
European Radiology|March 23, 2025
Magnetic resonance imaging for suspected perianal Crohn's disease in children: a multi-reader agreement studyPradipta Debnath, Michael R Acord, Christopher G Anton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Susan Groshen, Julie R Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G DuBois, Yael P Mosse, Elizabeth Fox, et al.
Pageof 5